Replies to post #102156 on Biotech Values

[oc631]

Good find ghmm. Looks like Roche hasn't given up on ITMN-191.

[DewDiligence]

The new ITMN-191 trial you cited is bearish for the ritonavir-boosted ITMN-191 program, IMO. Rather than progressing to a phase-2b study that measures SVR, Roche is evidently running another small PK/safety study.